$HBAN

Why is Huntington Bancshares stock sliding today? By Investing.com

Investing.com reports Huntington Bancshares (HBAN) shares fell 3.4% pre-open after Q2 2026 results missed Wall Street on EPS by about 1.4%, while revenue met estimates. Jefferies downgraded HBAN to Hold, cutting its price target to $19 from $21. Insider selling totaled about $4.4M over three months, amid margin pressure and integration concerns.

Original reporting
Published Jul 23, 2026, 12:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 23, 2026, 12:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$HBAN
Bearish
medium confidence
Mentioned
$HBAN
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$HBANBearishMed
01

Why it matters

HBAN’s pre-open drop is attributed to an EPS miss, a recent downgrade with a lower price target, and net insider selling, all under a risk-off market backdrop.

02

Market read

Traders get a same-day catalyst (EPS miss) plus a cited sell-side downgrade and insider selling, supporting a near-term risk-off stance on HBAN.

03

What to watch

The piece emphasizes EPS and sentiment but provides limited detail on the magnitude of provisions, NIM trend direction, and deposit-cost specifics that could change the forward outlook.

Relevance 7/10Novelty 6/10Timing: pre-open today after Q2 2026 earnings release

Background

The article frames HBAN’s move around Q2 2026 results, margin pressure, and integration challenges from prior acquisitions, alongside Fed rate-hike risk.

Company-level read

Ticker impact

$HBANBearishMedium confidence
Context

HBAN shares slid 3.4% pre-open after Q2 2026 earnings missed EPS by about 1.4% and revenue met estimates.

Expected impact

Likely continued volatility and selling pressure into the next earnings cycle unless deposit costs and NIM stabilize.

Evidence & confidence

The article cites a same-day pre-market reaction to an EPS miss, plus a July 6 Jefferies downgrade to Hold with a lower price target, and negative insider selling.

Market effects

Reinforces regional bank sensitivity to margin pressure, deposit-cost trajectory, and credit-provisioning assumptions.

US regional banks may see correlated weakness if investors generalize from HBAN’s EPS miss and integration concerns.

Limited direct global linkage; primarily a US rates and credit-cycle read-through.

Counterpoint

Revenue met consensus, and the article notes multiple large banks still maintain buy ratings, suggesting the selloff may be overdone versus fundamentals.

Key entities

  • Huntington Bancshares Incorporated

    Regional bank whose Q2 2026 earnings and subsequent downgrade are cited as drivers of today’s stock decline.

  • Jefferies

    Downgraded HBAN to Hold from Buy on July 6 and cut its price target to $19 from $21.

  • Federal Reserve

    June policy statement is cited as implying potential rate hikes that could pressure borrowers and credit risk.

Related articles

$HBANMed

Huntington Bancshares Q2 Earnings Call Highlights

Huntington Bancshares management said it is on track for $365 million in Cadence cost synergies in Q4 and $435 million in combined Veritex and Cadence run-rate expense synergies by Q4. Q2 average loans rose $15B (8.6%) and deposits rose $18.8B (9.2%). Net interest income was $2.1B (+8.5%); value-added fees rose over 60% YoY. Outlook: NII pressured by deposit costs; EPS target for 2027 is $1.90 to $1.93.

$HBANMed

HUNTINGTON BANCSHARES INC /MD/ (HBAN): Results of Operations and Financial Condition

HUNTINGTON BANCSHARES INC /MD/ (HBAN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 hban20260630_8kex992.htm EX-99.2 Document Exhibit 99.2 HUNTINGTON BANCSHARES INCORPORATED Quarterly Financial Supplement June 30, 2026 Table of Contents Quarterly Key Statistics 1 Year-to-Date Key Statistics 2 Consolidated Balance Sheets 4 Loans and Leases Composition 5

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

$JOBYMedAI 8/10

Joby Aviation Q2 Earnings Call Highlights

Joby Aviation (NYSE:JOBY) raised full-year revenue guidance to $115 million to $125 million from $105 million to $115 million. Q2 cash use was about $202 million and GAAP net loss was $245 million, including a $108 million non-cash warrant and earn-out fair value change. For 2H 2026, it expects $385 million to $415 million cash use. The company said aircraft availability is a key constraint on Blade routes and outlined manufacturing, infrastructure, and JV plans with Toyota.

$JHXMedAI 8/10

James Hardie Industries Q1 Earnings Call Highlights

James Hardie (NYSE:JHX) said about one-third of fiber-cement growth came from strategic initiatives, one-third from prior-year destocking comparisons, and the rest from price and mix. June sell-through rose 19%. Deck, Rail & Accessories sales fell 5% to $305.1M with 27.1% Adjusted EBITDA margin. Q2 net sales forecast $1.485B-$1.575B and FY2027 outlook raised; FCF Q1 was $254M and it redeemed $400M notes.

$IXMed

Orix Corp Ads Q1 Earnings Call Highlights

ORIX (NYSE: IX) discussed Q1 results and outlook on an earnings call, including potential Q3 Kioxia sale and valuation losses tied to Kioxia’s end-September share price. ORIX shifted its dividend basis to adjusted profits, targeting an interim dividend of JPY 107.27 per share and full-year JPY 187.36. It reported JPY 115.7B capital gains and about JPY 300B capital-recycling inflows, and continued a JPY 250B buyback.